Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
30 6월 2023 - 6:15AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of June 2023
Commission File Number: 001-12033
| Nymox Pharmaceutical Corporation |
| (Translation of registrant’s name into English) |
Bay & Deveaux Streets, Nassau, The Bahamas
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On June 27, 2023, shareholders owning a majority of outstanding shares of Nymox Pharmaceutical Corporation (the “Company”) stock approved the removal of Mr. Randall J. Lanham and Mr. Richard M. Cutler from the Board of Directors.
The Company is in the process of hiring a general counsel to assume Mr. Lanham’s legal duties and responsibilities to the Company, and to serve on the Board of Directors.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 29, 2023
| | NYMOX PHARMACEUTICAL CORPORATION | |
| | | | |
| By: | /s/ Paul Averback | |
| | Name: | Paul Averback | |
| | Title: | President and Chief Executive Officer | |
Nymox Pharmaceutical (NASDAQ:NYMX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
